CN109438513B - 含有取代膦酰胺酯的ido1抑制剂、其制备方法及应用 - Google Patents
含有取代膦酰胺酯的ido1抑制剂、其制备方法及应用 Download PDFInfo
- Publication number
- CN109438513B CN109438513B CN201811248840.4A CN201811248840A CN109438513B CN 109438513 B CN109438513 B CN 109438513B CN 201811248840 A CN201811248840 A CN 201811248840A CN 109438513 B CN109438513 B CN 109438513B
- Authority
- CN
- China
- Prior art keywords
- acid
- compound
- reaction
- added
- preparation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 229940043367 IDO1 inhibitor Drugs 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title abstract description 68
- 150000008298 phosphoramidates Chemical class 0.000 title abstract description 4
- 150000001875 compounds Chemical class 0.000 claims abstract description 125
- 102100040061 Indoleamine 2,3-dioxygenase 1 Human genes 0.000 claims abstract description 18
- 201000011510 cancer Diseases 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 36
- 230000001404 mediated effect Effects 0.000 claims description 28
- 206010028980 Neoplasm Diseases 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
- 150000003839 salts Chemical class 0.000 claims description 13
- 239000002253 acid Substances 0.000 claims description 11
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 9
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 239000003814 drug Substances 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 6
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 6
- 101710120843 Indoleamine 2,3-dioxygenase 1 Proteins 0.000 claims description 5
- 206010062016 Immunosuppression Diseases 0.000 claims description 4
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 claims description 4
- 229910000041 hydrogen chloride Inorganic materials 0.000 claims description 4
- 230000001506 immunosuppresive effect Effects 0.000 claims description 4
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 claims description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims description 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 3
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 3
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 3
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 claims description 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 claims description 3
- 235000015165 citric acid Nutrition 0.000 claims description 3
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 claims description 3
- 229940114124 ferulic acid Drugs 0.000 claims description 3
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 claims description 3
- 235000001785 ferulic acid Nutrition 0.000 claims description 3
- 229910000042 hydrogen bromide Inorganic materials 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- 230000004770 neurodegeneration Effects 0.000 claims description 3
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 3
- 235000006408 oxalic acid Nutrition 0.000 claims description 3
- 235000011007 phosphoric acid Nutrition 0.000 claims description 3
- 229940107700 pyruvic acid Drugs 0.000 claims description 3
- 239000011975 tartaric acid Substances 0.000 claims description 3
- 235000002906 tartaric acid Nutrition 0.000 claims description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 3
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 208000023275 Autoimmune disease Diseases 0.000 claims description 2
- 208000002177 Cataract Diseases 0.000 claims description 2
- 206010052779 Transplant rejections Diseases 0.000 claims description 2
- 210000000056 organ Anatomy 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 claims 2
- 101001037256 Homo sapiens Indoleamine 2,3-dioxygenase 1 Proteins 0.000 abstract description 13
- 238000002474 experimental method Methods 0.000 abstract description 11
- 230000002401 inhibitory effect Effects 0.000 abstract description 10
- 230000003285 pharmacodynamic effect Effects 0.000 abstract 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 80
- 238000006243 chemical reaction Methods 0.000 description 73
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 66
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 57
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 51
- 239000000243 solution Substances 0.000 description 48
- 239000002904 solvent Substances 0.000 description 41
- 238000005160 1H NMR spectroscopy Methods 0.000 description 40
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 40
- -1 nitro, hydroxy Chemical group 0.000 description 40
- 239000007787 solid Substances 0.000 description 40
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 39
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 29
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 26
- 238000000034 method Methods 0.000 description 25
- 239000000706 filtrate Substances 0.000 description 24
- 238000001035 drying Methods 0.000 description 23
- 239000012074 organic phase Substances 0.000 description 23
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 22
- 238000000967 suction filtration Methods 0.000 description 20
- 238000005406 washing Methods 0.000 description 20
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 20
- 238000001704 evaporation Methods 0.000 description 18
- 230000002829 reductive effect Effects 0.000 description 16
- 239000012636 effector Substances 0.000 description 14
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 14
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 13
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 12
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 12
- 238000000605 extraction Methods 0.000 description 12
- 239000011541 reaction mixture Substances 0.000 description 12
- 125000004432 carbon atom Chemical group C* 0.000 description 11
- 210000004027 cell Anatomy 0.000 description 11
- 239000007788 liquid Substances 0.000 description 11
- 238000010898 silica gel chromatography Methods 0.000 description 11
- KOWPUNQBGWIERF-UHFFFAOYSA-N 3-bromo-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Br)=C1 KOWPUNQBGWIERF-UHFFFAOYSA-N 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 238000010791 quenching Methods 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000008020 evaporation Effects 0.000 description 8
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 8
- AOCSUUGBCMTKJH-UHFFFAOYSA-N tert-butyl n-(2-aminoethyl)carbamate Chemical compound CC(C)(C)OC(=O)NCCN AOCSUUGBCMTKJH-UHFFFAOYSA-N 0.000 description 8
- HCNUSGQZCXEZIN-UHFFFAOYSA-N 3-[4-(2-aminoethylamino)-1,2,5-oxadiazol-3-yl]-4-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-one Chemical compound NCCNC1=NON=C1C1=NOC(=O)N1C1=CC=C(F)C(Br)=C1 HCNUSGQZCXEZIN-UHFFFAOYSA-N 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 125000004093 cyano group Chemical group *C#N 0.000 description 5
- 125000004122 cyclic group Chemical group 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000002367 halogens Chemical class 0.000 description 5
- 125000001072 heteroaryl group Chemical group 0.000 description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- YPBKTZBXSBLTDK-PKNBQFBNSA-N (3e)-3-[(3-bromo-4-fluoroanilino)-nitrosomethylidene]-4-[2-(sulfamoylamino)ethylamino]-1,2,5-oxadiazole Chemical compound NS(=O)(=O)NCCNC1=NON\C1=C(N=O)/NC1=CC=C(F)C(Br)=C1 YPBKTZBXSBLTDK-PKNBQFBNSA-N 0.000 description 4
- FCSKOFQQCWLGMV-UHFFFAOYSA-N 5-{5-[2-chloro-4-(4,5-dihydro-1,3-oxazol-2-yl)phenoxy]pentyl}-3-methylisoxazole Chemical compound O1N=C(C)C=C1CCCCCOC1=CC=C(C=2OCCN=2)C=C1Cl FCSKOFQQCWLGMV-UHFFFAOYSA-N 0.000 description 4
- 238000002835 absorbance Methods 0.000 description 4
- 229960000583 acetic acid Drugs 0.000 description 4
- BQSOOLYKWGLVHV-UHFFFAOYSA-N acetic acid 4-(dimethylamino)benzaldehyde Chemical compound C(C)(=O)O.CN(C1=CC=C(C=O)C=C1)C BQSOOLYKWGLVHV-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- 125000000753 cycloalkyl group Chemical group 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 229950006370 epacadostat Drugs 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 239000012044 organic layer Substances 0.000 description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L sodium carbonate Substances [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 235000010288 sodium nitrite Nutrition 0.000 description 4
- 238000001308 synthesis method Methods 0.000 description 4
- 229960004799 tryptophan Drugs 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- DHYHYLGCQVVLOQ-UHFFFAOYSA-N 3-bromoaniline Chemical group NC1=CC=CC(Br)=C1 DHYHYLGCQVVLOQ-UHFFFAOYSA-N 0.000 description 3
- YSEMCVGMNUUNRK-UHFFFAOYSA-N 3-chloro-4-fluoroaniline Chemical compound NC1=CC=C(F)C(Cl)=C1 YSEMCVGMNUUNRK-UHFFFAOYSA-N 0.000 description 3
- RHYOUOZNAPENIN-UHFFFAOYSA-N 4-(3-bromo-4-fluorophenyl)-3-(4-nitro-1,2,5-oxadiazol-3-yl)-1,2,4-oxadiazol-5-one Chemical compound BrC=1C=C(C=CC=1F)N1C(=NOC1=O)C1=NON=C1[N+](=O)[O-] RHYOUOZNAPENIN-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- RGSFGYAAUTVSQA-UHFFFAOYSA-N Cyclopentane Chemical compound C1CCCC1 RGSFGYAAUTVSQA-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 125000003118 aryl group Chemical group 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- AHZOHFYNIDGBKN-UHFFFAOYSA-N chloro(ethoxy)phosphinic acid Chemical compound CCOP(O)(Cl)=O AHZOHFYNIDGBKN-UHFFFAOYSA-N 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 210000002889 endothelial cell Anatomy 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 230000009036 growth inhibition Effects 0.000 description 3
- DMEGYFMYUHOHGS-UHFFFAOYSA-N heptamethylene Natural products C1CCCCCC1 DMEGYFMYUHOHGS-UHFFFAOYSA-N 0.000 description 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 3
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 238000010534 nucleophilic substitution reaction Methods 0.000 description 3
- 230000036961 partial effect Effects 0.000 description 3
- 238000009522 phase III clinical trial Methods 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 3
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 3
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 2
- YGPSJZOEDVAXAB-UHFFFAOYSA-N (R)-Kynurenine Natural products OC(=O)C(N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-UHFFFAOYSA-N 0.000 description 2
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 description 2
- ZSTVBWKWXBVZJB-UHFFFAOYSA-N 3-(4-amino-1,2,5-oxadiazol-3-yl)-4-(3-bromo-4-fluorophenyl)-1,2,4-oxadiazol-5-one Chemical compound NC1=NON=C1C1=NOC(=O)N1C1=CC=C(F)C(Br)=C1 ZSTVBWKWXBVZJB-UHFFFAOYSA-N 0.000 description 2
- DNFUTAVRGAVUKE-UHFFFAOYSA-N 4-amino-N'-hydroxy-1,2,5-oxadiazole-3-carboximidamide Chemical compound ON=C(N)C1=NON=C1N DNFUTAVRGAVUKE-UHFFFAOYSA-N 0.000 description 2
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 2
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 2
- 229940076838 Immune checkpoint inhibitor Drugs 0.000 description 2
- 102000037984 Inhibitory immune checkpoint proteins Human genes 0.000 description 2
- 108091008026 Inhibitory immune checkpoint proteins Proteins 0.000 description 2
- YGPSJZOEDVAXAB-QMMMGPOBSA-N L-kynurenine Chemical compound OC(=O)[C@@H](N)CC(=O)C1=CC=CC=C1N YGPSJZOEDVAXAB-QMMMGPOBSA-N 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-diisopropylethylamine Substances CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- WULYALUYOSLSSP-UHFFFAOYSA-N Nc1nonc1C(=N)N(O)c1ccc(F)c(Br)c1 Chemical compound Nc1nonc1C(=N)N(O)c1ccc(F)c(Br)c1 WULYALUYOSLSSP-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 229940041181 antineoplastic drug Drugs 0.000 description 2
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- MGNZXYYWBUKAII-UHFFFAOYSA-N cyclohexa-1,3-diene Chemical compound C1CC=CC=C1 MGNZXYYWBUKAII-UHFFFAOYSA-N 0.000 description 2
- LPIQUOYDBNQMRZ-UHFFFAOYSA-N cyclopentene Chemical compound C1CC=CC1 LPIQUOYDBNQMRZ-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 230000036267 drug metabolism Effects 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- 230000005284 excitation Effects 0.000 description 2
- 239000012065 filter cake Substances 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 125000000623 heterocyclic group Chemical group 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 239000012274 immune-checkpoint protein inhibitor Substances 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- AWJUIBRHMBBTKR-UHFFFAOYSA-N isoquinoline Chemical compound C1=NC=CC2=CC=CC=C21 AWJUIBRHMBBTKR-UHFFFAOYSA-N 0.000 description 2
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- AGJSNMGHAVDLRQ-IWFBPKFRSA-N methyl (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-amino-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,3-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoate Chemical compound SC[C@H](N)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(=O)OC)CC1=CC=C(O)C(C)=C1C AGJSNMGHAVDLRQ-IWFBPKFRSA-N 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- CLWDJTBJHITVPU-UHFFFAOYSA-N tert-butyl n-(1-aminobutyl)carbamate Chemical group CCCC(N)NC(=O)OC(C)(C)C CLWDJTBJHITVPU-UHFFFAOYSA-N 0.000 description 2
- IMFACGCPASFAPR-UHFFFAOYSA-N tributylamine Chemical compound CCCCN(CCCC)CCCC IMFACGCPASFAPR-UHFFFAOYSA-N 0.000 description 2
- JYEUMXHLPRZUAT-UHFFFAOYSA-N 1,2,3-triazine Chemical compound C1=CN=NN=C1 JYEUMXHLPRZUAT-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- DVONRBMAMGOSLY-UHFFFAOYSA-N 1-[chloro(methoxy)phosphoryl]oxyethane Chemical group CCOP(Cl)(=O)OC DVONRBMAMGOSLY-UHFFFAOYSA-N 0.000 description 1
- KAESVJOAVNADME-UHFFFAOYSA-N 1H-pyrrole Natural products C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- VIUDTWATMPPKEL-UHFFFAOYSA-N 3-(trifluoromethyl)aniline Chemical compound NC1=CC=CC(C(F)(F)F)=C1 VIUDTWATMPPKEL-UHFFFAOYSA-N 0.000 description 1
- PNPCRKVUWYDDST-UHFFFAOYSA-N 3-chloroaniline Chemical compound NC1=CC=CC(Cl)=C1 PNPCRKVUWYDDST-UHFFFAOYSA-N 0.000 description 1
- KRZCOLNOCZKSDF-UHFFFAOYSA-N 4-fluoroaniline Chemical compound NC1=CC=C(F)C=C1 KRZCOLNOCZKSDF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 210000003771 C cell Anatomy 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 102100035882 Catalase Human genes 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- PMPVIKIVABFJJI-UHFFFAOYSA-N Cyclobutane Chemical compound C1CCC1 PMPVIKIVABFJJI-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- BYHJHXPTQMMKCA-QMMMGPOBSA-N N-formyl-L-kynurenine Chemical compound [O-]C(=O)[C@@H]([NH3+])CC(=O)C1=CC=CC=C1NC=O BYHJHXPTQMMKCA-QMMMGPOBSA-N 0.000 description 1
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N N-phenyl amine Natural products NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- ZCQWOFVYLHDMMC-UHFFFAOYSA-N Oxazole Chemical compound C1=COC=N1 ZCQWOFVYLHDMMC-UHFFFAOYSA-N 0.000 description 1
- PQYQXANPPFKKLS-UHFFFAOYSA-N P(OC(C)C)(=O)Cl Chemical compound P(OC(C)C)(=O)Cl PQYQXANPPFKKLS-UHFFFAOYSA-N 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 208000008425 Protein deficiency Diseases 0.000 description 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 125000002490 anilino group Chemical group [H]N(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- 125000000480 butynyl group Chemical group [*]C#CC([H])([H])C([H])([H])[H] 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- ITVPBBDAZKBMRP-UHFFFAOYSA-N chloro-dioxido-oxo-$l^{5}-phosphane;hydron Chemical compound OP(O)(Cl)=O ITVPBBDAZKBMRP-UHFFFAOYSA-N 0.000 description 1
- 229940121657 clinical drug Drugs 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- CHVJITGCYZJHLR-UHFFFAOYSA-N cyclohepta-1,3,5-triene Chemical compound C1C=CC=CC=C1 CHVJITGCYZJHLR-UHFFFAOYSA-N 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- LHWWETDBWVTKJO-UHFFFAOYSA-N et3n triethylamine Chemical compound CCN(CC)CC.CCN(CC)CC LHWWETDBWVTKJO-UHFFFAOYSA-N 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 125000001153 fluoro group Chemical group F* 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 208000014829 head and neck neoplasm Diseases 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 102000006639 indoleamine 2,3-dioxygenase Human genes 0.000 description 1
- 108020004201 indoleamine 2,3-dioxygenase Proteins 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000000066 myeloid cell Anatomy 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen(.) Chemical compound [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- FYRHIOVKTDQVFC-UHFFFAOYSA-M potassium phthalimide Chemical compound [K+].C1=CC=C2C(=O)[N-]C(=O)C2=C1 FYRHIOVKTDQVFC-UHFFFAOYSA-M 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000002568 propynyl group Chemical group [*]C#CC([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- PPASLZSBLFJQEF-RKJRWTFHSA-M sodium ascorbate Substances [Na+].OC[C@@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RKJRWTFHSA-M 0.000 description 1
- 235000010378 sodium ascorbate Nutrition 0.000 description 1
- 229960005055 sodium ascorbate Drugs 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical class [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- PPASLZSBLFJQEF-RXSVEWSESA-M sodium-L-ascorbate Chemical compound [Na+].OC[C@H](O)[C@H]1OC(=O)C(O)=C1[O-] PPASLZSBLFJQEF-RXSVEWSESA-M 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- AKQXKEBCONUWCL-UHFFFAOYSA-N tert-butyl 3-aminopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(N)C1 AKQXKEBCONUWCL-UHFFFAOYSA-N 0.000 description 1
- WJFWBOPMLQVJOO-UHFFFAOYSA-N tert-butyl 3-aminopyrrole-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1C=CC(N)=C1 WJFWBOPMLQVJOO-UHFFFAOYSA-N 0.000 description 1
- LZRDHSFPLUWYAX-UHFFFAOYSA-N tert-butyl 4-aminopiperidine-1-carboxylate Chemical group CC(C)(C)OC(=O)N1CCC(N)CC1 LZRDHSFPLUWYAX-UHFFFAOYSA-N 0.000 description 1
- WUUZQZURHHSYSF-UHFFFAOYSA-N tert-butyl n-(1-aminopropyl)carbamate Chemical compound CCC(N)NC(=O)OC(C)(C)C WUUZQZURHHSYSF-UHFFFAOYSA-N 0.000 description 1
- RPSISDKVKZYNRL-UHFFFAOYSA-N tert-butyl n-[1-(aminomethyl)cyclopropyl]carbamate Chemical compound CC(C)(C)OC(=O)NC1(CN)CC1 RPSISDKVKZYNRL-UHFFFAOYSA-N 0.000 description 1
- WUOQXNWMYLFAHT-UHFFFAOYSA-N tert-butyl n-piperidin-3-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCCNC1 WUOQXNWMYLFAHT-UHFFFAOYSA-N 0.000 description 1
- CKXZPVPIDOJLLM-UHFFFAOYSA-N tert-butyl n-piperidin-4-ylcarbamate Chemical compound CC(C)(C)OC(=O)NC1CCNCC1 CKXZPVPIDOJLLM-UHFFFAOYSA-N 0.000 description 1
- 150000003536 tetrazoles Chemical class 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000009210 therapy by ultrasound Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6527—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having nitrogen and oxygen atoms as the only ring hetero atoms
- C07F9/653—Five-membered rings
- C07F9/65306—Five-membered rings containing two nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65586—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system at least one of the hetero rings does not contain nitrogen as ring hetero atom
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及药物化学领域,具体涉及一类含有取代膦酰胺酯衍生物的IDO1抑制剂(I)及其制备方法,药效学、药代学实验证明,本发明的化合物具有良好IDO1抑制活性及良好药代性质,可用于治疗恶性肿瘤等疾病。
Description
技术领域
本发明涉及医药领域,具体涉及一类含有取代膦酰胺酯的衍生物、立体异构体、其药学上可接受的盐、其合成方法及其在医药上的应用。
技术背景
近年来,应用免疫检查点抑制剂的免疫疗法在针对癌症晚期患者的治疗中表现出了高效、持久的抗肿瘤活性(Hodi,FS.et al.N Engl J Med,2010,363:711-723l;Schadendorf,D.et al.J Clin Oncol,2015,33:1889-1894)。然而,使用该类免疫检查点抑制剂进行的免疫疗法在众多恶性肿瘤患者中应答率较低(Kreamer,KM.et al.J Adv PractOncol,2014,5:418-431),这种现象指出在癌症治疗中仍有其他免疫调节通路存在的可能性。寻找、并针对这类调节通路而开发新型的药物将作为癌症治疗的新策略,对于增加癌症免疫疗法的应答率、适用性具有重要意义。
吲哚胺2,3-双加氧酶1(Indoleamine 2,3-dioxygenase 1,IDO1)是一种含亚铁血红素单体蛋白,由403个氨基酸残基组成,包括两个折叠的α-螺旋结构域,大结构域包含催化口袋,底物可在催化口袋中与IDO1发生疏水等作用,是催化色氨酸(Trp)氧化代谢为N-甲酰犬尿氨酸的第一限速酶(Mellor,AL.et al.Nat Rev Immunol,2004,4:762-774)。IDO1广泛分布在人和其他哺乳动物(兔、鼠)除肝脏以外的组织中,是肝脏以外唯一可催化色氨酸分解代谢的限速酶,而色氨酸是细胞维持活化和增殖所必须的氨基酸,也是构成蛋白质不可缺少的重要组成部分。IDO1可在多种类型细胞内表达,包括恶性上皮细胞和骨髓细胞,例如分布在肿瘤组织和肿瘤浸润的淋巴结中的巨噬细胞和树突状细胞。恶性细胞或非恶性细胞通过表达IDO1能够抑制T细胞免疫应答,最终导致免疫逃逸以及肿瘤过度生长(Munn,DH.et al.J Clin Invest,2007,117:1147-1154)。IDO1分解色氨酸使局部色氨酸耗竭进而产生分解代谢物如犬尿氨酸,这些共同导致T细胞的细胞周期停滞在G1期中期,促进T细胞与树突状细胞凋亡,最终抑制了肿瘤环境中的免疫监视作用,介导了肿瘤细胞逃逸免疫系统的攻击(Munn,DH.et al.J Exp Med,1999,189:1363-1372;Mezrich,JD.et al.JImmunol,2010,185:3190-3198)。另一方面,有研究表明色氨酸的其他分解代谢物也会抑制自然杀伤细胞的活性(Della,C.M.et al.Blood,2006,108:4118-4125)。而在一些癌症晚期患者中可以监测到其血清中色氨酸代谢物水平上调,这表明了IDO1活性水平异常提高,而IDO1高活性往往与预后不良相关联(Okamoto,A.et al.Clin Cancer Res,2005,11:6030-6039)。现已发现大多数人类肿瘤组成性表达IDO1,抑制IDO1的活性对于肿瘤治疗有着显著的促进作用。IDO1是一个具潜力的癌症免疫治疗的靶标,所以针对这种酶的特异性抑制剂具有治疗各种类型肿瘤的潜力。
IDO1抑制剂作为药物在医药行业具有良好的应用前景,但是目前尚未找到很好的IDO1抑制剂作为上市药物。为了达到更好的肿瘤治疗效果,我们希望开发新一代高效低毒的选择性IDO1抑制剂,表现出优异的效果与作用,优良的药代吸收活性。
发明内容
本发明旨在寻找结构新颖、活性高、副作用小以及具有良好药物代谢性质的抗肿瘤候选化合物。这些化合物通过单用或与其他抗肿瘤药物联用,从而达到提高现有抗肿瘤药物疗效并降低剂量和毒性的作用。
本发明公开了通式(I)的化合物、其立体异构体或其药学上可接受的盐。
A片段选自取代或未取代的C2~C8含氮杂环、取代或未取代的C1~C8氨基酰胺、其中取代基选自C1~C8烷基、卤素、氨基、硝基、羟基、C1~C6烷氧基、氰基、C3~C8环烷基、C3~C8杂环基、C5~C10芳基、C1~C10杂芳基中的一个或多个;m选自0、1、2、3或4;n选自1、2、3、4、5或6。
R1、R2各自独立地选自氢原子、氰基、氨基、卤素、取代或未取代的C1~C8烷基、C2~C8烯基、C2~C8炔基、羟基、硝基,其中取代基选自卤素、氨基、硝基、羟基或氰基中的一个或多个;
R3、R4各自独立地选自取代或未取代的C1~C8烷基、取代或未取代的C2~C8烯基、取代或未取代的C2~C8炔基、苄基、取代或未取代的C3~C8环烷基、取代或未取代的C3~C8杂环基、C5~C10芳基或C1~C10杂芳基;其中取代基选自卤素、氨基、硝基、羟基、氰基、C1~C3烷基或C1~C6杂芳基中的一个或多个。
在本发明的一个优选实施方案中,其中:
R1、R2各自独立地选自氢原子、氟原子、氯原子、溴原子、三氟甲基、二氟甲基;
R3、R4各自独立地选自甲基、乙基、丙基、异丙基、苯基、苄基、氰基甲基、2-呋喃甲基;
m代表0时,n代表1、2、3、4;
m代表1时,n代表1、2、3;
m代表2时,n代表2、3。
本发明所述的通式(I)的化合物的药学上可接受的盐,是指通式(I)的化合物与药学上可接受的酸形成的酸加成盐,所述酸包括:氯化氢、溴化氢、硫酸、碳酸、草酸、柠檬酸、琥珀酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、马来酸、甲磺酸、苯磺酸、对甲苯磺酸或阿魏酸。
本发明优选的部分化合物如下:
本发明的另一目的在于提供通式(I)所示化合物的制备方法::
由化合物I-1制备化合物I-2的过程,通过膦酰氯IV与A片段中氨基进行亲核取代反应得到;亲核取代所用去酸剂为N,N-二甲氨基吡啶、N,N-二异丙基乙胺、三丁胺或三乙胺,优选三乙胺;所用溶剂为四氢呋喃或二氯甲烷,优选二氯甲烷。
由化合物I-2制备化合物I的过程,通过在碱性条件下反应得到;所用碱为氢氧化钠、氢氧化钾或碳酸钾,优选氢氧化钠;所用溶剂为甲醇、乙醇或四氢呋喃,优选四氢呋喃。
在一种实施方式中,当其为通式(II)所示化合物时
更具体的方法包括:
由化合物VI制备化合物VII的过程,反应试剂可以为亚硝酸钠或盐酸,溶剂可以为水。
由化合物VII经重氮化制备化合物VIII的过程,反应试剂为亚硝酸钠、盐酸、氯化钠或冰醋酸,反应溶剂为水。
由化合物VIII经亲核取代反应制备化合物X的过程,反应物为取代苯胺(IX),去酸剂为碳酸氢钠、碳酸钠、三乙胺,溶剂为水、乙酸乙酯、二氯甲烷、四氢呋喃。
由化合物X制备化合物XI的过程,反应物为N,N-羰基二咪唑(CDI),溶剂为四氢呋喃、乙酸乙酯或二氯甲烷。
由化合物XI经氧化反应制备化合物XII的过程,氧化剂为30%过氧化氢,溶剂为浓硫酸或三氟乙酸。
由化合物XII制备化合物XIV的过程,反应物为N-叔丁氧羰基保护的脂肪胺(XIII),所用碱为氢氧化钠或氢氧化钾,溶剂为甲醇、乙醇、四氢呋喃、二氯甲烷或乙酸乙酯。
由化合物XIV制备化合物III的过程,所用酸为三氟乙酸或氯化氢,溶剂为二氯甲烷、四氢呋喃、乙酸乙酯或二氧六环。
由化合物III制备化合物V的过程,反应物为IV,去酸剂为N,N-二甲氨基吡啶、N,N-二异丙基乙胺、三丁胺或三乙胺,溶剂为四氢呋喃或二氯甲烷。
由化合物V通过碱水解制备通式化合物(II)的过程,所用碱为氢氧化钠、氢氧化钾或碳酸钾,溶剂为甲醇、乙醇或四氢呋喃。
所述通式(I)化合物的药学上可接受的盐可通过与等化学当量或过量酸(无机酸或有机酸)在合适的溶剂或溶剂组合物中反应制得。所述酸包括但不限于氯化氢、溴化氢、硫酸、碳酸、草酸、柠檬酸、琥珀酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、马来酸、甲磺酸、苯磺酸、对甲苯磺酸或阿魏酸。所述溶剂包括但不限于甲醇、乙醇、二氯甲烷、丙酮、乙酸乙酯、甲苯或四氢呋喃,或任意几种混合溶剂。
本发明提供了一种药物组合物,其包括药物有效量的活性组分和药学上可接受的辅料;所述活性组分包括通式(I)化合物、其立体异构体和药学上可接受的盐中的一种或多种。所述药物组合物中,所述辅料包括药学上可接受的载体、稀释剂和/或赋形剂。
根据治疗目的可将药物组合物制成各种类型的给药单位剂型,如片剂、丸剂、粉剂、液体、悬浮液、乳液、颗粒剂、颗粒剂、胶囊和针剂(溶液或悬浮液)等,优选片剂、胶囊、液体、悬浮液和针剂(溶液或悬浮液)。
本发明所述化合物在临床上的给药方式可采用口服、注射等方式。
一般地,本发明的化合物用于治疗时,人用剂量范围为1-1000mg/天。也可根据剂型的不同和疾病严重程度,使用剂量超出该范围。
本发明还提供通式(I)所示化合物在制备吲哚胺2,3-双加氧酶1抑制剂中的应用。
本发明还提供通式(I)所示化合物在用于治疗吲哚胺2,3-双加氧酶1介导的免疫抑制的相关疾病中的应用。
本发明所述的吲哚胺2,3-双加氧酶1介导的免疫抑制的相关疾病包括癌症、病毒感染、神经变性疾病、白内障、器官移植排斥、抑郁症或自身免疫性疾病。其中癌症优选肺癌、黑色素瘤、头颈癌、肾细胞癌或尿路上皮癌。病毒感染优选HIV感染。神经变性疾病优选阿尔兹海默病。
除非另外说明,在说明书和权利要求中使用的以下术语具有下面讨论的含义:
术语“烷基”表示1-20个碳原子的饱和的脂烃基,包括直链和支链基团(本申请书中提到的数字范围,例如“1-8”,是指该基团,此时为烷基,可以含1个碳原子、2个碳原子、3个碳原子等,直至包括8个碳原子)。烷基可以是取代的或未取代的。当是取代的烷基时,该取代基优选是一或多个,更优选1-3个,最优选1或2个取代基。
术语“烯基”指直链、支链或环状的,主链含有12~18个碳原子及至少一个碳-碳双键的非芳香烃基。因此,“C12-C18烯基”指主链具有12~18个碳原子的烯基。烯基包括乙烯基、丙烯基、丁烯基、2-甲基丁烯基和环己烯基等。烯基的直链、支链或环状部分可含有双键且如果指明了取代的烯基则此部分可被取代。
术语“炔基”指直链、支链或环状的,主链含有12~18个碳原子及至少一个碳碳三键的非芳香烃基。因此,“C12-C18炔基”指具有12~18个碳原子的炔基。炔基包括乙炔基、丙炔基、丁炔基、3-甲基丁炔基等。炔基的直链、支链或环状部分可含有三键且如果指明了取代的炔基则此部分可被取代。
术语“卤素”表示氟、氯、溴或碘,优选为氟、氯、溴。
术语“氨基”表示-NH2基团。
术语“硝基”表示-NO2基团。
术语“羟基”表示-OH基团。
术语“氰基”表示-CN基团。
术语“烷氧基”表示-O-(未取代的烷基)和-O-(未取代的环烷基)。代表性实例包括但不限于甲氧基、乙氧基、丙氧基、丁氧基、环丙氧基、环丁氧基、环戊氧基、环己氧基等。
术语“环烷基”表示全部为碳的单环或稠合的环(“稠合”环意味着系统中的每个环与系统中的其它环共享毗邻的一对碳原子)基团,其中一个或多个环不具有完全连接的π电子系统,环烷基的实例(不局限于)为环丙烷、环丁烷、环戊烷、环戊烯、环己烷、金刚烷、环己二烯、环庚烷和环庚三烯。环烷基可为取代的和未取代的。
术语“杂环基”表示3到8个环原子的饱和环状基团,其中一个或两个环原子是选自N、O或S(O)m(其中m是0至2的整数)的杂原子,其余环原子是C,其中一个或两个C原子可以可选地被羰基代替。
术语“芳基”表示1至12个碳原子的全碳单环或稠合多环基团,具有完全共轭的π电子系统。芳基的非限制性实例有苯基、萘基和蒽基。芳基可以是取代的或未取代的。
术语“杂芳基”表示5至12个环原子的单环或稠合环基团,含有一个、两个、三个或四个选自N、O或S的环杂原子,其余环原子是C,另外具有完全共轭的π电子系统。未取代的杂芳基地非限制性实例有吡咯、呋喃、噻吩、咪唑、噁唑、噻唑、吡唑、嘧啶、喹啉、异喹啉、嘌呤、四唑、三嗪和咔唑。杂芳基可以是取代的或未取代的。
具体实施方式
为了进一步阐释本发明,下面给出一系列实施例,这些实施例完全是例证性的,它们仅用来对本发明具体描述,不应当理解为对本发明的限制。
实施例1
4-氨基-N-羟基-1,2,5-噁二唑-3-甲脒(VII)的制备
将20.7g(300mmol)亚硝酸钠和40mL水加入到500mL反应瓶中,搅拌溶解,室温下缓慢滴加9.9g(150mmol)丙二腈的150mL的2mol/L盐酸溶液,室温搅拌过夜,冷却至0℃,滴加盐酸羟胺(23g,340mmol)的40mL水溶液,搅拌30min,20℃以下用10N氢氧化钠调节pH至10,升至35℃反应2h,再加热回流2h。冷却至室温,反应液用20mL乙酸乙酯萃取,减压蒸除溶剂的白色固体,将水层放置过夜,析出固体,抽滤,水洗,滤饼与减压蒸馏的白色固体合并干燥得白色粉末状固体14.9g,收率68%。1HNMR(300MHz,DMSO-d6):δ=10.46(s,1H),6.24(s,2H),6.02(s,2H);HRMS(ESI):m/z[M+H]+.Calcd for C3H5N5O2 143.0516,found 143.0518。
4-氨基-N-羟基-1,2,5-噁二唑-3-碳酰亚胺基氯(VIII)的制备
将42.2g(295mmol)的化合物VII、600mL水、300mL乙酸和6mol/L盐酸(150mL,870mmol)加入到2L三颈瓶中,升温至45℃,搅拌至化合物VII完全溶解,加入氯化钠(50.8g,870mmol),搅拌溶解,冷却降温至0℃,缓慢加入亚硝酸钠溶于70mL水溶液,0℃下搅拌8h,升至室温,抽滤,滤饼水洗得淡黄色粉末24.5g,收率51%。1H NMR(300MHz,DMSO-d6):δ=13.39(s,1H),6.29(s,2H);HRMS(ESI):m/z[M+H]+.Calcd for C3H3ClN4O2 161.9872,found:161.9872。
4-氨基-N-(3-溴-4-氟苯基)-N-羟基-1,2,5噁二唑-3-甲脒(X-1)的制备
将33.8g(208mmol)化合物VIII、300mL水加入到1L三颈瓶中,升温至60℃,加入3-溴4-氟苯胺(43.6g,229mmol),随后加入碳酸氢钠(26.3g,313mmol)的300mL水溶液,反应1h,TLC监测反应,待化合物VIII反应完全后停止反应。降温至室温后用乙酸乙酯萃取(2×300mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得米白色固体59.3g,收率89%。1HNMR(300MHz,DMSO-d6):δ=11.46(s,1H),8.89(s,1H),6.99(t,J=8.8Hz,1H),6.81(dd,J1=6.0Hz,J2=2.7Hz,1H),6.56-6.51(m,1H),6.28(s,2H)ppm;HRMS(ESI):m/z[M+H]+.Calcd for C9H8BrFN5O2 315.9840,found 315.9842。
3-(4-氨基-1,2,5-噁二唑-3-基)-4-(3-溴-4-氟苯基)-1,2,4-噁二唑-5-(4H)-酮(XI-1)的制备
将化合物X-1(10g,31.64mmol)、乙酸乙酯(200mL)加入到500mL三颈瓶中,加入N,N-羰基二咪唑(CDI,11.5g,96mmol),25℃下反应2h,TLC监测反应,待反应完全后加入1mol/L盐酸(100mL)洗涤,有机层经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得白色固体9.9g,收率92%。1H NMR(300MHz,DMSO-d6):δ=8.10(dd,J1=6.2Hz,J2=2.4Hz,1H),7.74(m,1H),7.61(t,J=8.7Hz,1H),6.63(s,2H)ppm;HRMS(ESI):m/z[M+H]+.Calcd forC10H6BrFN5O2341.9633,found 341.9638。
4-(3-溴-4-氟苯基)-3-(4-硝基-1,2,5-噁二唑-3-基)-1,2,4-噁二唑-5(4H)-酮(XII-1)的制备
将化合物XI-1(0.34g,1mmol)加入6mL三氟乙酸中,加入5mL双氧水(30%),于50℃反应8h,TLC监测反应。待反应结束后加入饱和亚硫酸钠溶液淬灭反应,用乙酸乙酯萃取(2×15mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得黄色固体0.28g,收率75%。HRMS(APCI):m/z[M]-.Calcd for C10H3BrFN5O5 341.9302,found 370.9305。
实施例2
叔丁基(2-((4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)氨基)乙基)碳酸酯(XIV-1)的制备
将化合物XII-1(0.37g,1mmol)加入10mL四氢呋喃中,加入N-叔丁氧羰基乙二胺(0.32g,2mmol),加入1mol/L氢氧化钠溶液(1.5mL),于25℃下反应1h,TLC监测反应。待反应结束后,加入1mol/L盐酸调节pH至3,用乙酸乙酯萃取(3×15mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,硅胶柱层析纯化得淡黄色固体0.35g,收率72%。1H NMR(300MHz,DMSO-d6):δ=8.08(dd,J1=6.2Hz,J2=2.5Hz,1H),7.72(m,1H),7.60(t,J=8.7Hz,1H),6.94(m,1H),6.52(m,1H),3.30(m,2H),3.18(m,2H),1.38(s,9H)ppm;HRMS(ESI):m/z[M]-.Calcd for C17H19BrFN6O5 485.0579,found 485.0583。
3-(4-((2-氨基乙基)氨基)-1,2,5-噁二唑-3-基)-4-(3-溴4-氟苯基)-1,2,4-噁二唑-5(4H)-酮(III-1)的制备
将化合物XIV-1(0.48g,1mmol)加入到20mL二氯甲烷中,加入3mL三氟乙酸,于25℃下反应4h,TLC监测反应。待反应结束后,加入饱和碳酸氢钠溶液调节pH至8,用乙酸乙酯萃取(3×20mL),合并有机相,经无水硫酸钠干燥,减压蒸除溶剂得淡黄色固体0.35g,收率91%。1H NMR(300MHz,DMSO-d6):δ=8.12(m,4H),7.76(m,1H),7.58(t,J=8.7Hz,1H),6.78(t,J=6.7Hz,1H),3.51(dd,J1=11.8Hz,J2=6.1Hz,2H),3.02(m,2H)ppm;HRMS(ESI):m/z[M+H]+.Calcd for C12H11BrFN6O3 385.0055,found 385.0051。
N-(2-((4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-甲基膦酸甲酯(V-1)的制备
将化合物III-1(0.19g,0.5mmol)加入到10mL二氯甲烷中,冷却至0℃,加入三乙胺(0.15g,1.5mmol),反应液在0℃下反应1h。于0℃下,将甲基氯代膦酸甲酯(IV-1,0.13g,1mmol,采用公知的方法“JOrg Chem,2009,74:9319-9327”制备而得)加入到反应液中,升至室温反应2h,TLC监测反应。待反应完毕后,加入饱和碳酸氢钠溶液将反应淬灭,分液,有机相依次用水洗,饱和氯化钠溶液洗涤,无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,经硅胶柱层析纯化得淡黄色固体0.22g,收率93%。1H NMR(300MHz,DMSO-d6):δ=8.85(s,1H),7.19(t,J=8.7Hz,1H),7.13(dd,J1=6.1Hz,J2=2.5Hz,1H),6.82-6.76(m,1H),6.24(t,J=6.1Hz,1H),4.72-4.65(m,1H),3.51(d,J=11.0Hz,3H),3.27-3.21(m,1H),2.98-2.97(m,1H),1.33(d,J=16.1Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Calcd for C14H16BrFN6O5477.0082,found 477.0078。
N-(2-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-甲基膦酸甲酯(CPU-P1)的制备
将化合物V-1(0.1g,0.2mmol)加入到10mL四氢呋喃中,加入2N氢氧化钠溶液(0.5mL),于25℃下反应4h,TLC监测反应。待反应完毕后加入1mol/L盐酸调节pH至3,加入乙酸乙酯萃取(2×10mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色固体50mg,收率55%。1HNMR(300MHz,DMSO-d6):δ=11.44(s,1H),8.82(s,1H),7.20(t,J=8.7Hz,1H),7.12(dd,J1=6.0Hz,J2=2.6Hz,1H),6.80-6.75(m,1H),6.25(t,J=6.0Hz,1H),4.73-4.65(m,1H),3.48(d,J=11Hz,3H),3.29-3.23(m,1H),2.99-2.96(m,1H),1.33(d,J=16.2Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C13H18BrFN6O4P:451.0289,found:451.0291。
实施例3
N-(2-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-甲基膦酸乙酯(CPU-P2)的制备
用甲基氯代膦酸乙酯(0.14g,1mmol)代替甲基氯代膦酸甲酯之外,以与化合物CPU-P1相同的方法合成得淡黄色固体139mg,收率75%。1HNMR(300MHz,DMSO-d6):δ=11.50(s,1H),8.92(s,1H),7.19(t,J=8.7Hz,1H),7.12(dd,J1=5.7Hz,J2=2.0Hz,1H),6.78-6.75(m,1H),6.26(t,J=4.7Hz,1H),4.75-4.68(m,1H),3.87-3.80(m,2H),3.26(d,J=6.0Hz,2H),2.95(sbr,2H),1.33(d,J=16.4Hz,3H),1.17(t,J=6.7Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C14H20BrFN6O4P:465.0446,found:465.0445。
实施例4
N-(2-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-甲基膦酸异丙酯(CPU-P3)的制备
用甲基氯代膦酸异丙酯(0.16g,1mmol)代替甲基氯代膦酸甲酯之外,以与化合物CPU-P1相同的方法合成得到淡黄色固体65mg,收率23%。1HNMR(300MHz,DMSO-d6):δ=11.44(s,1H),8.85(s,1H),7.18(t,J=8.6Hz,1H),7.11(s,1H),6.79-6.77(m,1H),6.24(s,1H),4.63-4.60(m,1H),4.48-4.44(m,1H),3.26(sbr,2H),2.96(sbr,2H),1.31(d,J=16.5Hz,3H),1.19(s,6H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C15H22BrFN6O4P:481.0582,found:481.0589。
实施例5
N-(2-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-乙基膦酸乙酯(CPU-P4)的制备
用乙基氯代膦酸乙酯(0.16g,1mmol)代替甲基氯代膦酸甲酯之外,以与化合物CPU-P1相同的方法合成得到淡红色固体62mg,收率25%。1HNMR(300MHz,DMSO-d6):δ=11.42(s,1H),8.85(s,1H),7.18(t,J=8.7Hz,1H),7.11(dd,J1=6.0Hz,J2=2.6Hz,1H),6.79-6.76(m,1H),6.24(t,J=6.0Hz,1H),4.62-4.59(m,1H),3.89-3.82(m,2H),3.29-3.22(m,2H),2.99-2.94(m,2H),1.60-1.52(m,2H),1.18(t,J=7.0Hz,3H),1.04-0.93(m,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C15H22BrFN6O4P:479.0602,found:479.0595。
实施例6
N-(2-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-丙基膦酸乙酯(CPU-P5)的制备
用乙基氯代膦酸丙酯(0.17g,1mmol)代替甲基氯代膦酸甲酯之外,以与化合物CPU-P1相同的方法合成得到淡黄色油状物76mg,收率33%。1H NMR(300MHz,DMSO-d6):δ=11.48(s,1H),8.91(s,1H),7.19(t,J=8.7Hz,1H),7.11(dd,J1=6.1Hz,J2=2.7Hz,1H),6.79-6.74(m,1H),6.26(t,J=5.9Hz,1H),4.68-4.60(m,1H),3.88-3.80(m,2H),3.27-3.21(m,2H),2.99-2.92(m,2H),1.58-1.42(m,4H),1.17(t,J=7.1Hz,3H),0.92(t,J=7.2Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C16H24BrFN6O4P:493.0759,found:493.0752。
实施例7
N-(2-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-苯基膦酸乙酯(CPU-P6)的制备
用苯基氯代膦酸乙酯(0.20g,1mmol)代替甲基氯代膦酸甲酯之外,以与化合物CPU-P1相同的方法合成得到红色固体94mg,收率60%。1H NMR(300MHz,DMSO-d6):δ=11.47(s,1H),8.90(s,1H),7.74-7.62(m,2H),7.53-7.47(m,3H),7.18(t,J=8.7Hz,1H),7.10(d,J=3.5Hz,1H),6.78-6.75(m,1H),6.24-6.23(m,1H),5.22-5.16(m,1H),4.03-3.91(m,3H),3.25-3.23(m,2H),2.96-2.94(m,2H),1.24-0.94(m,3H);HRMS(ESI):m/z[M+H]+.Cacld forC19H20BrFN6O4P:527.0602,found:527.0609。
实施例8
N-(2-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-苄基膦酸乙酯(CPU-P7)的制备
用苄基氯代膦酸乙酯(0.21g,1mmol)代替甲基氯代膦酸甲酯之外,以与化合物CPU-P1相同的方法合成得到淡红色固体85mg,收率36%。1HNMR(300MHz,DMSO-d6):δ=11.46(s,1H),8.89(s,1H),7.25(sbr,5H),7.17(t,J=8.8Hz,1H),7.10(dd,J1=5.8Hz,J2=2.4Hz,1H),6.78-6.75(m,1H),6.21(t,J=5.5Hz,1H),4.76-4.68(m,1H),3.87-3.83(m,2H),3.18-3.17(m,2H),3.09(s,1H),3.02(s,1H),2.94-2.88(m,2H),1.17-1.10(m,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C20H24BrFN6O4P:543.0738,found:543.0742。
实施例9
N-(2-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-氰甲基膦酸乙酯(CPU-P8)的制备
用氰甲基氯代膦酸乙酯(0.17g,1mmol)代替甲基氯代膦酸甲酯之外,以与化合物CPU-P1相同的方法合成得到淡黄色固体36mg,收率21%。1HNMR(300MHz,DMSO-d6):δ=11.50(s,1H),8.92(s,1H),7.19(t,J=8.7Hz,1H),7.12(dd,J1=5.7Hz,J2=2.0Hz,1H),6.78-6.75(m,1H),6.26(t,J=4.7Hz,1H),4.75-4.68(m,1H),3.91-3.88(m,2H),3.32(d,J=6.0Hz,2H),3.01(sbr,2H),2.83(d,J=16.8Hz,3H),1.17(t,J=6.7Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C15H19BrFN6O4P:492.0378,found:492.0362。
实施例10
N-(2-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-2-呋喃甲基膦酸乙酯(CPU-P9)的制备
用2-呋喃甲基氯代膦酸乙酯(0.17g,1mmol)代替甲基氯代膦酸甲酯之外,以与化合物CPU-P1相同的方法合成得到淡黄色固体62mg,收率59%。1HNMR(300MHz,DMSO-d6):δ=11.47(s,1H),8.88(s,1H),7.27(d,J=1.7Hz,1H),7.17(t,J=8.8Hz,1H),7.11(dd,J1=5.8Hz,J2=2.4Hz,1H),6.26(dd,J1=2.9Hz,J2=1.7Hz,1H),6.78-6.75(m,1H),6.23(t,J=5.5Hz,1H),5.96(d,J=2.9Hz,1H),4.74-4.65(m,1H),3.87-3.82(m,2H),3.17-3.15(m,2H),3.08(s,1H),3.02(s,1H),2.94-2.88(m,2H),1.16-1.10(m,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C18H22BrFN6O5P:532.2866,found:532.2867。
实施例11
N-(2-((4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)氨基)丙基)-P-甲基膦酸甲酯(V-2)的制备
将化合物III-2(0.40g,1.0mmol,用N-叔丁氧羰基丙二胺代替N-叔丁氧羰基乙二胺外,以化合物III-1以相同的方法制得到)加入到20mL二氯甲烷中,冷却至0℃,加入三乙胺(0.30g,3.0mmol),反应液在0℃下反应1h。于0℃下,将甲基氯代膦酸甲酯(IV-1,0.26g,2mmol)加入到反应液中,升至室温反应2h,TLC监测反应。待反应完毕后,加入饱和碳酸氢钠溶液将反应淬灭,分液,有机相依次用水洗,饱和氯化钠溶液洗涤,无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,经硅胶柱层析纯化得淡黄色固体0.31g,收率64%。HRMS(ESI):m/z[M+H]+.Cacld for C15H18BrFN5O4P:491.0238,found:491.0242。
N-(3-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)-P-甲基膦酸甲酯(CPU-P10)的制备
将化合物V-2(0.31g,0.6mmol)加入到10mL四氢呋喃中,加入2N氢氧化钠溶液(0.5mL),于25℃下反应4h,TLC监测反应。待反应完毕后加入1mol/L盐酸调节pH至3,加入乙酸乙酯萃取(2×10mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色固体138mg,收率48%。1HNMR(300MHz,DMSO-d6):δ=11.58(s,1H),8.91(s,1H),7.19(t,J=8.7Hz,1H),7.11(d,J=3.3Hz,1H),6.78-6.77(m,1H),6.39(s,1H),4.78-4.73(m,1H),3.35(d,J=11.1Hz,3H),3.27-3.26(d,J=5.7Hz,2H),2.86-2.83(m,2H),1.71-1.69(m,2H),1.35(d,J=16.3Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C14H20N6O4P:465.0446,found:465.0444。
实施例12
N-(3-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)-P-乙基膦酸乙酯(CPU-P11)的制备
用乙基氯代膦酸乙酯(0.16g,1mmol)代替甲基氯代膦酸甲酯之外,以与化合物CPU-P10相同方法合成得到淡黄色固体83mg,收率54%。1H NMR(300MHz,DMSO-d6):δ=11.58(s,1H),8.89(s,1H),7.19(t,J=8.8Hz,1H),7.11(dd,J1=6.0Hz,J2=3.3Hz,1H),6.79-6.74(m,1H),6.38(t,J=5.6Hz,1H),4.67-4.59(m,1H),3.94-3.80(m,2H),3.29-3.23(m,2H),2.89-2.79(m,2H),1.73-1.64(m,2H),1.62-1.51(m,2H),1.19(t,J=7.0Hz,3H),1.03(dt,J1=18.9Hz,J2=7.6Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C16H24BrFN6O4P:493.0759,found:493.0754。
实施例13
N-(3-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)-P-丙基膦酸乙酯(CPU-P12)的制备
用丙基氯代膦酸乙酯(0.17g,1mmol)代替甲基氯代膦酸甲酯之外,以与化合物CPU-P10相同方法合成得到淡黄色固体46mg,收率36%。1H NMR(300MHz,DMSO-d6):δ=11.58(s,1H),8.89(s,1H),7.18(t,J=8.7Hz,1H),7.11(dd,J1=6.0Hz,J2=2.6Hz,1H),6.79-6.74(m,1H),6.38(t,J=5.6Hz,1H),4.66-4.58(m,1H),3.92-3.81(m,2H),3.29-3.23(m,2H),2.99-2.78(m,2H),1.73-1.64(m,2H),1.59-1.42(m,4H),1.18(t,J=7.0Hz,3H),0.94(t,J=7.2Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C17H26BrFN6O4P:509.0895,found:509.0901。
实施例14
N-(3-((4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)氨基)丁基)-P-甲基膦酸甲酯(V-3)的制备
将化合物III-3(0.21g,0.5mmol,用N-叔丁氧羰基丁二胺代替N-叔丁氧羰基乙二胺外,以化合物III-1相同的方法制得到)加入到10mL二氯甲烷中,冷却至0℃,加入三乙胺(0.15g,1.5mmol),反应液在0℃下反应1h。于0℃下,将甲基氯代膦酸甲酯(0.13g,1mmol)加入到反应液中,升至室温反应2h,TLC监测反应。待反应完毕后,加入饱和碳酸氢钠溶液将反应淬灭,分液,有机相依次用水洗,饱和氯化钠溶液洗涤,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,经硅胶柱层析纯化得淡黄色固体0.27g,收率54%。HRMS(ESI):m/z[M+H]+.Cacld for C16H20BrFN6O5P:505.0395,found:505.0387。
N-(3-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丁基)-P-甲基膦酸甲酯(CPU-P13)的制备
将化合物V-3(0.1g,0.2mmol)加入到10mL四氢呋喃中,加入2N氢氧化钠溶液(0.5mL),于25℃下反应4h,TLC监测反应。待反应完毕后加入1mol/L盐酸调节pH至3,加入乙酸乙酯萃取(2×10mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色固体43mg,收率46%.1HNMR(300MHz,DMSO-d6):δ=11.52(s,1H),8.92(s,1H),7.19(t,J=8.7Hz,1H),7.12(dd,J1=6.0Hz,J2=2.6Hz,1H),6.78-6.73(m,1H),6.18(t,J=5.7Hz,1H),4.62-4.56(m,1H),3.47(d,J=11.1Hz,3H),3.22-3.16(m,2H),2.79-2.72(m,2H),1.60-1.53(m,2H),1.46-1.38(m,2H),1.32(d,J=16.2Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacldfor C15H22BrFN6O4P:481.0582,found:481.0597。
实施例15
N-(3-((4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)氨基)戊基)-P-甲基膦酸甲酯(V-4)的制备
将化合物III-4(0.22g,0.5mmol,用N-叔丁氧羰基丁二胺代替N-叔丁氧羰基乙二胺外,以化合物III-1相同的方法制得到)加入到10mL二氯甲烷中,冷却至0℃,加入三乙胺(0.15g,1.5mmol),反应液在0℃下反应1h。于0℃下,将甲基氯代膦酸甲酯(0.13g,1mmol)加入到反应液中,升至室温反应2h,TLC监测反应。待反应完毕后,加入饱和碳酸氢钠溶液将反应淬灭,分液,有机相依次用水洗,饱和氯化钠溶液洗涤,无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,经硅胶柱层析纯化得淡黄色固体0.18g,收率68%。HRMS(ESI):m/z[M+H]+.Cacldfor C17H22BrFN6O5P:519.0551,found:519.0559。
N-(3-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)戊基)-P-甲基膦酸甲酯(CPU-P14)的制备
将化合物V-4(0.18g,0.34mmol)加入到10mL四氢呋喃中,加入2N氢氧化钠溶液(0.5mL),于25℃下反应4h,TLC监测反应。待反应完毕后加入1mol/L盐酸调节pH至3,加入乙酸乙酯萃取(2×10mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色固体31mg,收率18%。1HNMR(300MHz,DMSO-d6):δ=11.47(s,1H),8.89(s,1H),7.21(t,J=8.7Hz,1H),7.12(dd,J1=6.1Hz,J2=2.5Hz,1H),6.75-6.71(m,1H),6.18(t,J=5.7Hz,1H),4.63-4.57(m,1H),3.44(d,J=11.1Hz,3H),3.23-3.17(m,2H),2.79-2.72(m,2H),1.60-1.53(m,2H),1.52-1.47(m,2H),1.43-1.35(m,2H),1.33(d,J=16.1Hz,3H);HRMS(ESI):m/z[M+H]+.Cacld for C16H24BrFN6O4P:495.0738,found:495.0728。
实施例16
N-(4-((4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)氨基)哌啶-1-基)-P-甲基膦酸甲酯(V-5)的制备
将化合物III-5(0.22g,0.5mmol,用N-叔丁氧羰基-4-氨基哌啶代替N-叔丁氧羰基乙二胺外,以化合物III-1相同的方法制得到)加入到10mL二氯甲烷中,冷却至0℃,加入三乙胺(0.15g,1.5mmol),反应液在0℃下反应1h。于0℃下,将甲基氯代膦酸甲酯(0.13g,1mmol)加入到反应液中,升至室温反应2h,TLC监测反应。待反应完毕后,加入饱和碳酸氢钠溶液将反应淬灭,分液,有机相依次用水洗,饱和氯化钠溶液洗涤,无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,经硅胶柱层析纯化得淡黄色固体0.22g,收率86%。HRMS(ESI):m/z[M+H]+.Cacld for C17H20BrFN6O5P:517.0395,found:517.0399。
N-(4-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)哌啶-1-基)-P-甲基膦酸甲酯(CPU-P15)的制备
将化合物V-5(0.22g,0.43mmol)加入到10mL四氢呋喃中,加入2N氢氧化钠溶液(0.5mL),于25℃下反应4h,TLC监测反应。待反应完毕后加入1mol/L盐酸调节pH至3,加入乙酸乙酯萃取(2×10mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色固体158mg,收率75%。1H NMR(300MHz,DMSO-d6):δ=11.47(s,1H),8.92(s,1H),7.18(t,J=8.6Hz,1H),7.11-7.10(m,1H),6.77-6.75(m,1H),6.18(d,J=7.2Hz,1H),3.48(d,J=11.1Hz,3H),3.38(sbr,2H),2.77(sbr,2H),1.99-1.90(m,2H),1.38(d,J=16.1Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C16H22BrFN6O4P:493.0582,found:493.0587。
实施例17
N-(4-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)哌啶-1-基)-P-乙基膦酸乙酯(CPU-P16)的制备
用乙基氯代膦酸乙酯(0.16g,1mmol)代替甲基氯代膦酸甲酯之外,以化合物CPU-P15以相同的方法合成得到淡黄色固体140mg,收率54%。1H NMR(300MHz,DMSO-d6):δ=11.45(s,1H),8.91(s,1H),7.18(t,J=8.8Hz,1H),7.12(dd,J1=6.0Hz,J2=2.7Hz,1H),6.79-6.74(m,1H),6.18(d,J=7.2Hz,1H),3.92-3.77(m,2H),3.44-3.39(m,3H),2.80-2.72(m,2H),1.94(d,J=10.8Hz,2H),1.69-1.56(m,2H),1.34(d,J=11.2Hz,2H),1.27(t,J=7.0Hz,3H),1.02(dt,J1=19.2Hz,J2=7.6Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld forC18H26BrFN6O4P:521.0895,found:521.0885。
实施例18
N-(4-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)哌啶-1-基)-P-丙基膦酸乙酯(CPU-P17)的制备
用丙基氯代膦酸乙酯(0.17g,1mmol)代替甲基氯代膦酸甲酯之外,以化合物CPU-P15相同的方法合成化合物得到淡黄色固体96.3mg,收率36%。1H NMR(300MHz,DMSO-d6):δ=11.45(s,1H),8.91(s,1H),7.18(t,J=8.7Hz,1H),7.12-7.09(m,1H),6.79-6.74(m,1H),6.18(d,J=7.3Hz,1H),3.89-3.79(m,2H),3.34-3.38(m,3H),2.78-2.71(m,2H),1.94(d,J=10.2Hz,2H),1.65-1.57(m,2H),1.51-1.43(m,2H),1.34(d,J=12Hz,2H),1.20(t,J=7.0Hz,3H),0.95(t,J=7.3Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C19H28BrFN6O4P:535.1051,found:535.1072。
实施例18
N-(3-((4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)氨基)哌啶-1-基)-P-甲基膦酸甲酯(V-6)的制备
将化合物III-6(0.21g,0.5mmol,用N-叔丁氧羰基-3-氨基哌啶代替N-叔丁氧羰基乙二胺外,以化合物III-1相同的方法制得到)加入到10mL二氯甲烷中,冷却至0℃,加入三乙胺(0.15g,1.5mmol),反应液在0℃下反应1h。于0℃下,将甲基氯代膦酸甲酯(0.13g,1mmol)加入到反应液中,升至室温反应2h,TLC监测反应。待反应完毕后,加入饱和碳酸氢钠溶液将反应淬灭,分液,有机相依次用水洗,饱和氯化钠溶液洗涤,无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,经硅胶柱层析纯化得淡黄色固体0.22g,收率85%。HRMS(ESI):m/z[M+H]+.Cacld for C17H20BrFN6O5P:517.0395,found:517.0394。
N-(3-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)哌啶-1-基)-P-甲基膦酸甲酯(CPU-P18)的制备
将化合物V-6(0.12g,0.42mmol)加入到10mL四氢呋喃中,加入2N氢氧化钠溶液(0.5mL),于25℃下反应4h,TLC监测反应。待反应完毕后加入1mol/L盐酸调节pH至3,加入乙酸乙酯萃取(2×10mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色固体69mg,收率34%。1H NMR(300MHz,DMSO-d6):δ=11.51(s,1H),8.92(s,1H),7.19(t,J=8.7Hz,1H),7.12-7.10(m,1H),6.79-6.77(m,1H),6.18-6.17(m,1H),3.49-3.40(m,3H),3.20-3.16(m,2H),2.79-2.72(m,2H),1.93-1.91(m,1H),1.56-1.46(m,4H),1.33(t,J=17.0Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C16H22BrFN6O4P:491.0602,found:491.0600。
实施例20
N-(3-((4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)氨基)吡咯-1-基)-P-甲基膦酸甲酯(V-7)的制备
将化合物III-7(0.21g,0.5mmol,用N-叔丁氧羰基-3-氨基吡咯代替N-叔丁氧羰基乙二胺外,以化合物III-1相同的方法制得到)加入到10mL二氯甲烷中,冷却至0℃,加入三乙胺(0.15g,1.5mmol),反应液在0℃下反应1h。于0℃下,将甲基氯代膦酸甲酯(0.13g,1mmol)加入到反应液中,升至室温反应2h,TLC监测反应。待反应完毕后,加入饱和碳酸氢钠溶液将反应淬灭,分液,有机相依次用水洗,饱和氯化钠溶液洗涤,无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,经硅胶柱层析纯化得淡黄色固体0.15g,收率61%。HRMS(ESI):m/z[M+H]+.Cacld for C16H18BrFN6O5P:503.0238,found:503.0241。
N-(3-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)吡咯-1-基)-P-甲基膦酸甲酯(CPU-P19)的制备
将化合物V-7(0.15g,0.3mmol)加入到10mL四氢呋喃中,加入2N氢氧化钠溶液(0.5mL),于25℃下反应4h,TLC监测反应。待反应完毕后加入1mol/L盐酸调节pH至3,加入乙酸乙酯萃取(2×10mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色固体67mg,收率47%。1HNMR(300MHz,DMSO-d6):δ=11.51(s,1H),8.90(s,1H),7.30(t,J=8.6Hz,1H),7.24-7.21(m,1H),6.84-6.80(m,1H),6.25-6.21(m,1H),3.59-3.44(m,2H),3.48(d,J=11.1Hz,3H),3.19-3.05(m,2H),2.89-2.76(m,2H),2.73-2.68(m,1H),1.81-1.56(m,2H),1.53-1.43(m,2H),1.26(d,J=16.1Hz,3H);HRMS(ESI):m/z[M+H]+.Cacld forC15H20BrFN6O4P:477.0446,found:477.0443。
实施例21
4-(4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)哌嗪-1-基)-甲基亚膦酸甲酯(V-8)的制备
将化合物III-8(0.21g,0.5mmol,用N-叔丁氧羰基哌嗪代替N-叔丁氧羰基乙二胺外,以化合物III-1相同的方法制得到)加入到10mL二氯甲烷中,冷却至0℃,加入三乙胺(0.15g,1.5mmol),反应液在0℃下反应1h。于0℃下,将甲基氯代膦酸甲酯(0.13g,1mmol)加入到反应液中,升至室温反应2h,TLC监测反应。待反应完毕后,加入饱和碳酸氢钠溶液将反应淬灭,分液,有机相依次用水洗,饱和氯化钠溶液洗涤,无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,经硅胶柱层析纯化得淡黄色固体0.20g,收率81%。HRMS(ESI):m/z[M+H]+.Cacldfor C16H18BrFN6O5P:505.0238,found:505.0243.
4-(4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)-哌嗪-1-基)-甲基亚膦酸甲酯(CPU-P20)的制备
将化合物V-8(0.20g,0.4mmol)加入到10mL四氢呋喃中,加入2N氢氧化钠溶液(0.5mL),于25℃下反应4h,TLC监测反应。待反应完毕后加入1mol/L盐酸调节pH至3,加入乙酸乙酯萃取(2×10mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色固体150mg,收率79%。1H NMR(300MHz,DMSO-d6):δ=11.25 and 10.39(s,7:3,1H),9.21and 9.15(s,3:7,1H),8.09-8.06 and 6.69-6.63(m,7:3,1H),7.39-7.27 and 7.20-7.14(m,3:7,1H),3.48(d,J=11.2Hz,3H),3.29-3.26(m,1H),3.13-3.06(m,4H),2.98(s,3H),1.39(d,J=16.3Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C15H20BrFN6O4P:477.0446,found:477.0443。
实施例22
N-(1-(4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)哌嗪-4-基)-P-甲基膦酸甲酯(CPU-P21)的制备
参照化合物CPU-P20的制备方法,用4-叔丁氧羰基氨基哌啶代替N-叔丁氧羰基哌嗪,以相同的合成方法得到化合物CPU-P21(73mg,收率75%)。1H NMR(300MHz,DMSO-d6):δ=11.47(s,1H),8.91(s,1H),7.18(t,J=8.7Hz,1H),7.12(dd,J1=6.1Hz,J2=2.7Hz,1H),6.79-6.74(m,1H),6.17(d,J=7.2Hz,1H),3.48(d,J=11.1Hz,3H),3.41-3.37(m,3H),2.82-2.72(m,2H),1.94-1.91(m,2H),1.43-1.29(m,2H),1.38(d,J=16.2Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld forC16H22BrFN6O4P:491.0602,found:491.0599。
实施例23
N-(1-(4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)哌嗪-3-基)-P-甲基膦酸甲酯(CPU-P21)的制备
参照化合物CPU-P20的制备方法,用3-叔丁氧羰基氨基哌啶代替N-叔丁氧羰基哌嗪,以相同的合成方法得到化合物CPU-P22(86mg,收率88%)。1H NMR(300MHz,DMSO-d6):δ=11.68 and 10.37(s,7:3,1H),9.22 and 9.11(s,3:7,1H),8.10-8.07 and 6.71-6.67(m,7:3,1H),7.37-7.27 and 7.20-7.12(m,3:7,1H),4.78-4.69(m,1H),3.49(dd,J1=11.1Hz,J2=1.7Hz,3H),3.40(d,J=11.2Hz,1H),2.90-2.78(m,1H),2.74-2.62(m,1H),1.90-1.78(m,1H),1.72-1.65(m,1H),1.35(dd,J1=16.3Hz,J2=1.8Hz,3H),1.27-1.22(m,3H),0.85(d,J=16.3Hz,1H)ppm;HRMS(ESI):m/z[M+H]+.Cacld forC16H22BrFN6O4P:491.0602,found:491.0594。
实施例24
N-(2-((4-(N-(4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-甲基膦酸甲酯(CPU-P23)的制备
参照化合物CPU-P1的制备方法,用4-氟苯胺代替3-溴-4-氟苯胺,以相同的合成方法得到化合物CPU-P23(55mg,收率65%)。1H NMR(300MHz,DMSO-d6):δ=11.25(s,1H),8.72(s,1H),7.01(t,J=8.7Hz,2H),6.83-6.78(m,2H),6.26-6.23(m,1H),4.75-4.70(m,1H),3.47(d,J=11.1Hz,3H),3.29-3.20(m,2H),2.97-2.91(m,2H),1.33(d,J=16.3Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C13H19FN6O4P:373.1184,found:373.1180。
实施例25
N-(2-((4-(N-(3-溴苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-甲基膦酸甲酯(CPU-P24)的制备
参照化合物CPU-P1的制备方法,用3-溴苯胺代替3-溴-4-氟苯胺,以相同的合成方法得到化合物CPU-P24(75mg,收率86%)。1H NMR(300MHz,DMSO-d6):δ=11.61(s,1H),8.92(s,1H),7.13-7.04(m,2H),6.97(t,J=1.8Hz,1H),6.72-6.68(m,1H),6.26(t,J=5.8Hz,1H),4.78-4.71(m,1H),3.48(d,J=11.1Hz,3H),3.29-3.23(m,2H),3.01-2.94(m,2H),1.33(d,J=16.4Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C13H19BrN6O4P:433.0383,found:433.0380。
实施例26
N-(2-((4-(N-(3-溴苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-乙基膦酸乙酯的(CPU-P25)制备
参照化合物CPU-P5的制备方法,用3-溴苯胺代替3-溴-4-氟苯胺,以相同的合成方法得到化合物CPU-P25(80mg,收率87%)。1H NMR(300MHz,DMSO-d6):δ=11.54(s,1H),8.94(s,1H),7.13-7.04(m,2H),6.97(sbr,1H),6.71(d,J=7.7Hz,1H),6.25(t,J=5.8Hz,1H),4.68-4.60(m,1H),3.92-3.78(m,3H),3.29-3.23(m,2H),3.01-2.94(m,2H),1.62-1.49(m,2H),1.17(t,J=7.0Hz,3H),1.01(dt,J1=18.9Hz,J2=7.6Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C15H23BrN6O4P:461.0696,found:461.0689。
实施例27
N-(3-((4-(N-(3-溴苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)-P-甲基膦酸甲酯(CPU-P26)的制备
参照化合物CPU-P10的制备方法,用3-溴苯胺代替3-溴-4-氟苯胺,以相同的合成方法得到化合物CPU-P26(42mg,收率47%)。1H NMR(300MHz,DMSO-d6):δ=11.64(s,1H),8.95(s,1H),7.14-7.04(m,2H),6.97(sbr,1H),6.71(d,J=7.5Hz,1H),6.37(t,J=5.6Hz,1H),4.77-4.69(m,1H),3.50(d,J=11.1Hz,3H),3.30-3.24(m,2H),2.88-2.78(m,2H),1.72-1.66(m,2H),1.35(d,J=16.2Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.CacldforC14H21BrN6O4P:447.0540,found:447.0541。
实施例28
N-(2-((4-(N-(3-氯苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-甲基膦酸甲酯的(CPU-P27)制备
参照化合物CPU-P1的制备方法,用3-氯苯胺代替3-溴-4-氟苯胺,以相同的合成方法得到化合物CPU-P27(57mg,收率74%)。1H NMR(300MHz,DMSO-d6):δ=11.56(s,1H),8.95(s,1H),7.17(t,J=8.0Hz,1H),6.94(d,J=8.0Hz,1H),6.83(s,1H),6.68(d,J=7.8Hz,1H),6.25(t,J=6.0Hz,1H),4.79-4.71(m,1H),3.48(d,J=11.1Hz,3H),3.27-3.23(m,2H),2.99-2.94(m,2H),1.34(d,J=16.3Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.CacldforC13H19ClN6O4P:389.0888,found:389.0898。
实施例29
N-(2-((4-(N-(3-(三氟甲基)-苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-甲基膦酸甲酯(CPU-P28)的制备
参照化合物CPU-P1的制备方法,用3-氨基三氟甲苯代替3-溴-4-氟苯胺,以相同的合成方法得到化合物CPU-P28(70mg,收率84%)。1H NMR(300MHz,DMSO-d6):δ=11.64(s,1H),9.11(s,1H),7.39(t,J=8.0Hz,1H),7.23(d,J=7.6Hz,1H),7.08(sbr,1H),7.00(d,J=6.0Hz,1H),6.27(t,J=5.6Hz,1H),4.79-4.72(m,1H),3.48(d,J=11.1Hz,3H),3.30-3.24(m,2H),2.99-2.94(m,2H),1.34(d,J=16.3Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacldfor C14H19F3N6O4P:423.1152,found:423.1152。
实施例30
N-(2-((4-(N-(3-氯-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-甲基膦酸甲酯(CPU-P29)的制备
参照化合物CPU-P1的制备方法,用3-氯-4-氟苯胺代替3-溴-4-氟苯胺,以相同的合成方法得到化合物CPU-P21(38mg,收率47%)。1H NMR(300MHz,DMSO-d6)::δ=11.57(s,1H),8.91(s,1H),7.22(t,J=9.1Hz,1H),7.00(dd,J1=6.5Hz,J2=2.7Hz,1H),6.76-6.70(m,1H),6.37(t,J=5.6Hz,1H),4.67-4.69(m,1H),3.50(d,J=11.1Hz,3H),3.30-3.23(m,2H),2.88-2.78(m,2H),1.74-1.65(m,2H),1.35(d,J=16.2Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld for C13H18ClFN6O4P:407.0794,found:407.0793。
实施例31
N-(3-((4-(N-(3-氯-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)丙基)-P-甲基膦酸甲酯(CPU-P30)的制备
参照化合物CPU-P10的制备方法,用3-氯-4-氟苯胺代替3-溴-4-氟苯胺,以相同的合成方法得到化合物CPU-P30(46mg,收率55%)。1H NMR(300MHz,DMSO-d6):δ=11.57(s,1H),8.91(s,1H),7.22(t,J=9.1Hz,1H),7.00(dd,J1=6.5Hz,J2=2.7Hz,1H),6.76-6.70(m,1H),6.37(t,J=5.6Hz,1H),4.67-4.69(m,1H),3.50(d,J=11.1Hz,3H),3.30-3.23(m,2H),2.88-2.78(m,2H),1.74-1.65(m,2H),1.35(d,J=16.2Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld forC14H20ClFN6O4P:421.0951,found:421.0956。
实施例32
N-(2-((4-(N-(3-(三氟甲基)-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)乙基)-P-甲基膦酸甲酯(CPU-P31)的制备
参照化合物CPU-P1的制备方法,用3-氯-4-氟苯胺代替3-溴-4-氟苯胺,以相同的合成方法得到化合物CPU-P31(72mg,收率82%)。1H NMR(300MHz,DMSO-d6):δ=11.58(s,1H),9.07(s,1H),7.32(t,J=9.7Hz,1H),7.16(dd,J1=6.1Hz,J2=2.6Hz,1H),7.08-7.03(m,1H),6.26(t,J=6.0Hz,1H),6.27(t,J=5.6Hz,1H),4.79-4.71(m,1H),3.48(d,J=11.1Hz,3H),3.29-3.23(m,2H),3.01-2.93(m,2H),1.33(d,J=16.3Hz,3H)ppm;HRMS(ESI):m/z[M+H]+.Cacld forC14H18F4N6O4P:441.1058,found:441.1057。
实施例33
2-溴-N-(4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-2H-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)乙酰胺(XII-1)的制备
将化合物XI(3.4g,10mmol)加入到50mL二氯甲烷中,冷却至-20℃,加入三乙胺(3.0g,30mmol),在-20℃下滴加溴乙酰溴(4.0g,20mmol)。反应在-20℃下进行4h,TLC检测反应完毕,升至室温,缓慢加入50mL水,分液,有机层经无水硫酸钠干燥后减压蒸除溶剂,经硅胶柱层析纯化得到白色固体1.89g,收率41%。HRMS(ESI):m/z[M-H]-.Cacld forC12H5Br2FN5O4P:461.8677,found:461.8749。
N-(4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)1,2,5-噁二唑-3-基)-2-(1,3-二氧代异吲哚啉-2-基)乙酰胺(XIII-1)的制备
将化合物XIII-1(1.0g,2.15mmol)加入到20mL无水DMF中,加入酞酰亚胺钾(1.19g,6.15mmol),在25℃下反应8h,TLC检测反应完毕,加入50mL冰水,用乙酸乙酯(2×20mL)萃取,合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色固体0.92g,收率81%。HRMS(ESI):m/z[M-H]-.Cacld for C20H10BrFN6O6:526.9756,found:526.9750。
2-氨基-N-(4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)乙酰胺(XIV-1)的制备
将化合物XIII-1(0.53g,1mmol)加入到8mL的6m mol/L盐酸溶液中,加热至回流10h。TLC检测反应完毕后,将反应液降温至0℃,用饱和碳酸钠水溶液调节pH至8,加入乙酸乙酯(3×20mL)萃取,合并有机层,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色固体0.19g,收率47%。HRMS(ESI):m/z[M-H]-.Cacld for C12H8BrFN6O4:398.9847,found:398.9844。
N-(2-((4-(4-(3-溴-4-氟苯基)-5-氧代-4,5-二氢-1,2,4-噁二唑-3-基)-1,2,5-噁二唑-3-基)氨基)-2氧代乙基)-P-甲基膦酸甲酯(XV-1)的制备
将化合物XIV-1(0.20g,0.5mmol)加入到10mL二氯甲烷中,冷却至0℃,加入三乙胺(0.15g,1.5mmol),反应液在0℃下反应1h。于0℃下,将甲基氯代膦酸甲酯(0.13g,1mmol)加入到反应液中,升至室温反应2h,TLC监测反应。待反应完毕后,加入饱和碳酸氢钠溶液将反应淬灭,分液,有机相依次用水洗,饱和氯化钠溶液洗涤,无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂,经硅胶柱层析纯化得淡黄色固体0.12g,收率48%。HRMS(ESI):m/z[M+H]+.Cacldfor C14H13BrFN6O6P:490.9874,found:490.9877。
N-(2-((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)-氨基)-2-氧代乙基)-P-甲基膦酸甲酯(CPU-P22)的制备
将化合物XV-1(0.12g,0.24mmol)加入到10mL四氢呋喃中,加入2N氢氧化钠溶液(0.5mL),于25℃下反应4h,TLC监测反应。待反应完毕后加入1mol/L盐酸调节pH至3,加入乙酸乙酯萃取(2×10mL),合并有机相,经无水硫酸钠干燥,抽滤,滤液减压蒸除溶剂得淡黄色固体32mg,收率29%。1HNMR(300MHz,DMSO-d6):δ=11.46(s,1H),10.61(s,1H),8.88(s,1H),7.25(t,J=8.6Hz,1H),7.13(dd,J1=6.0Hz,J2=2.6Hz,1H),6.82-6.77(m,1H),6.35(t,J=6.0Hz,1H),3.53(s,2H),3.48(d,J=11Hz,3H),3.29-3.23(m,1H),2.99-2.96(m,1H),1.33(d,J=16.2Hz,3H);HRMS(ESI):m/z[M+H]+.Cacld for C13H16BrFN6O5P:465.0082,found:465.0092。
实施例34
N-(1-(((4-(N-(3-溴-4-氟苯基)-N-羟基甲脒基)-1,2,5-噁二唑-3-基)氨基)甲基)环丙基)-P-甲基膦酸甲酯(CPU-P33)的制备
参照化合物CPU-P1的制备方法,用1-(氨基甲基)环丙基氨基甲酸叔丁酯代替N-叔丁氧羰基乙二胺,以相同的合成方法得到化合物CPU-P23(15mg,收率29%)。1HNMR(300MHz,DMSO-d6):δ=11.54(s,1H),8.89(s,1H),7.27(t,J=8.7Hz,1H),7.09(dd,J1=6.0Hz,J2=2.6Hz,1H),6.70-6.65(m,1H),6.25(t,J=6.1Hz,1H),4.73-4.65(m,1H),3.48(d,J=11Hz,3H),3.29-3.23(m,1H),1.33(d,J=16.2Hz,3H),0.94(s,2H),0.68(s,2H);HRMS(ESI):m/z[M+H]+.Cacld for C15H20BrFN6O4P:477.0446,found:477.0449。
以下是本发明部分化合物的药理学试验及结果:
一、本发明部分化合物在酶水平抑制IDO1活性
实验方法:
配制pH值为6.5的50mmol磷酸钾缓冲液,其中含有抗坏血酸钠25mmol、亚甲基蓝10μM、过氧化氢酶100μg/mL、L-色氨酸100μM。将系列浓度稀释的化合物加96孔板中,每孔加入提取的IDO1酶,保证每孔终体积为200μL,37℃孵育1h。取140μL上清液加入新的96孔板中,每孔加入10μL 30%三氯乙酸水溶液或1N NaOH水溶液于60℃水解30min。水解完毕后于0℃下10000rpm离心10min。用三氯乙酸水解时,取100μL上清液与新96孔透明板中,加100μL2%(w/v)的对二甲氨基苯甲醛醋酸溶液,室温下混匀2min,在480nm下测每孔的吸光度。用NaOH水解时取100μL上清液于白色96孔板中,在360nm激发光下测460nm的发射光强度。用L-犬尿氨酸为标准物制作两条标准曲线。配制系列浓度的标准物(200、100、50、25、12.5、6.25、3.12、1.56μmol),(1)每个浓度下取100μL与等体积的2%(w/v)的对二甲氨基苯甲醛醋酸溶液混匀,在480nm下测吸光度。(2)每个浓度下用取100μL于96孔白板中,在360nm激发光下测460nm的发射光强度。非线性回归(Graphpad prism)来分析数据生成IC50值。利用上述方法,对化合物的IDO1抑制活性进行测定,其中IC50如下,并用目前处于III期临床实验的IDO1抑制剂Epacadostat作为对照。
实验结果如表所示。
表1本发明部分化合物对IDO1的抑制活性IC50
由表1可见,本发明部分化合物对IDO1由良好抑制活性。
二、本发明部分化合物对Hela细胞内IDO1蛋白酶抑制活性的测定
实验方法:
用含有10%FBS的RPMI 1640细胞培养液将Hela细胞培养至对数期,用胰酶消化并制成浓度为5×104个/mL的细胞悬液,在保证每孔5000个细胞的情况下将细胞接种在透明96孔板中放于37℃细胞培养箱中培养24h。待细胞在96孔板中贴壁并生长出形态,弃去原培养基,将IFN-γ人干扰素(20ng/孔)和系列浓度稀释的化合物加入96孔板中(保证每孔终体积为200μL)放于细胞培养箱中培养48h。将原96孔板中140μL培养液上清液移至新的96孔板中,每孔加入10μL 6.1N的三氯醋酸水溶液于60℃下水解30min。水解完毕后将96孔板放于离心机中,于0℃下以4000rpm离心20min。离心完毕后将100mL上清液移至新的96孔透明板中,每孔加入100μL 2%(w/v)的对二甲氨基苯甲醛醋酸溶液,室温下混匀2min,在480nm下测每孔的吸光度。用L-犬尿氨酸为标准物制作标准曲线。配制系列浓度的标准物(200、100、50、25、12.5、6.25、3.12、1.56μM),每个浓度下取100μL与等体积的2%(w/v)的对二甲氨基苯甲醛醋酸溶液混匀,在480nm下测吸光度。用非线性回归(Graphpad prism)来分析数据生成IC50值。实验设置3个复孔。利用上述方法,对化合物的IDO1抑制活性进行测定,其中IC50如下。用目前处于III期临床实验的IDO1抑制剂Epacadostat作为对照。
实验结果如表所示:
表2本发明部分化合物基于Hela细胞的IDO1抑制活性IC50
由表2可见,本发明部分化合物对Hela细胞中的IDO1具有良好抑制活性。
三、本发明化合物对B16F10移植瘤的生长抑制率
实验方法:
收集生长旺盛期的鼠黑色素瘤细胞B16F10,在无菌条件下制备成细胞悬液,接种于C57BL6小鼠腋下。C57BL6小鼠移植瘤用游标卡尺测量移植瘤直径,待肿瘤生长至一定大小后将动物分组,每组5只。使用测量瘤径的方法,动态观察被试化合物抗肿瘤的效应。空白对照给予等剂量0.5%羧甲基纤维素钠,灌胃给药;化合物组进行腹腔注射,给药量80mg/Kg,隔天一次,持续15天。从给药当天开始测量肿瘤长径(a)和短径(b),每隔一天测量一次,肿瘤体积=ab^2/2。15天后处死荷瘤C57BL6小鼠,并分离瘤块称重。所得数据进行统计学处理,计算抑瘤率,并用目前处于III期临床试验的IDO1抑制剂Epacadostat作为对照。
实验结果如下表所示:
表3本发明代表化合物对B16F10移植瘤的生长抑制率
由表3可见,本发明代表化合物CPU-P1、CPU-P4、CPU-P10对B16F10移植瘤具有较好的生长抑制率。
四、本发明化合物CPU-P1、CPU-P4、CPU-P10的药代动力学测试
实验方法:
以SD大鼠为受试动物,应用LC/MS/MS法测定了大鼠经灌胃给予CPU-P1、CPU-P2、CPU-P10化合物后不同时刻血浆中药物浓度。称取适量药物,加入二甲亚砜配制成0.1mg/μL,后加入0.5%羧甲基纤维素钠水溶液稀释至5mg/mL,超声制成混悬液。将选好的SD大鼠共12只,分成3组,雌雄各半,禁食一夜后分别灌胃给药,给药量20mg/Kg。灌胃给药组于给药前及给药后0.5、1.0、2.0、4.0、6.0、8.0、11.0、24.0h由眼眶采血0.1mL,置于肝素化试管中,3500rpm离心10min分离血浆,于-20℃保存,给药后2h进食。用LC/MS/MS法测定不同化合物灌胃给药后大鼠血浆中的待测化合物含量。
实验结果如表所示:
表4本发明化合物药物代谢动力学实验
由表4可见,本发明化合物相较于III期临床药物Epacadostat具有更好的药物代谢性质。
Claims (6)
2.根据权利要求1所述的化合物或其药学上可接受的盐,其特征在于,药学上可接受的盐,是指通式(I)的化合物与药学上可接受的酸形成的酸加成盐,所述酸包括:氯化氢、溴化氢、硫酸、碳酸、草酸、柠檬酸、琥珀酸、酒石酸、磷酸、乳酸、丙酮酸、乙酸、马来酸、甲磺酸、苯磺酸、对甲苯磺酸或阿魏酸。
3.一种药物组合物,其包括药物有效量的活性组分和药学上可接受的辅料;所述活性组分包括权利要求1所述的化合物或其药学上可接受的盐中的一种或多种。
4.权利要求1所述化合物或其药学上可接受的盐或权利要求3所述的药物组合物在制备吲哚胺2,3-双加氧酶1抑制剂中的应用。
5.权利要求1所述化合物或其药学上可接受的盐或权利要求3所述的药物组合物在制备用于治疗吲哚胺2,3-双加氧酶1介导的免疫抑制的相关疾病药物中的应用。
6.根据权利要求5所述的应用,其特征在于,所述吲哚胺2,3-双加氧酶1介导的免疫抑制的相关疾病为癌症、病毒感染、神经变性疾病、白内障、器官移植排斥、抑郁症或自身免疫性疾病。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811248840.4A CN109438513B (zh) | 2018-10-25 | 2018-10-25 | 含有取代膦酰胺酯的ido1抑制剂、其制备方法及应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201811248840.4A CN109438513B (zh) | 2018-10-25 | 2018-10-25 | 含有取代膦酰胺酯的ido1抑制剂、其制备方法及应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN109438513A CN109438513A (zh) | 2019-03-08 |
CN109438513B true CN109438513B (zh) | 2020-05-12 |
Family
ID=65548154
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201811248840.4A Active CN109438513B (zh) | 2018-10-25 | 2018-10-25 | 含有取代膦酰胺酯的ido1抑制剂、其制备方法及应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109438513B (zh) |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3389783A4 (en) * | 2015-12-15 | 2019-05-15 | Merck Sharp & Dohme Corp. | NOVEL COMPOUNDS THAN INDOLAMINE-2,3-DIOXYGENASE INHIBITORS |
BR112019001980A2 (pt) * | 2016-08-02 | 2019-05-07 | Shandong Luye Pharmaceutical Co., Ltd. | inibidor de ido1 e método de preparação e aplicação do mesmo |
CN107954999B (zh) * | 2016-10-17 | 2023-01-24 | 上海医药集团股份有限公司 | 含噁二唑环化合物、制备方法、中间体、组合物及应用 |
CN106967005B (zh) * | 2017-04-07 | 2019-07-16 | 上海肇钰医药科技有限公司 | 一种能抑制ido的化合物、其制备方法及其用途 |
-
2018
- 2018-10-25 CN CN201811248840.4A patent/CN109438513B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN109438513A (zh) | 2019-03-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017294231B2 (en) | Aromatic acetylene or aromatic ethylene compound, intermediate, preparation method, pharmaceutical composition and use thereof | |
KR102185928B1 (ko) | 벤질아민 유도체 | |
JP7352297B2 (ja) | ピリドン誘導体と、その組成物、並びにそれらが抗ウイルス薬物としての応用 | |
CN112424194B (zh) | 免疫调节剂及其组合物和制备方法 | |
JP6348978B2 (ja) | グリオキサミド置換ピロールアミド誘導体およびb型肝炎を処置するための医薬品としてのその使用 | |
CN110167939B (zh) | 吡咯并[2,3-c]吡啶类衍生物、其制备方法及其在医药上的应用 | |
CN112566900B (zh) | 免疫调节剂及其组合物和制备方法 | |
CN111138301A (zh) | 联苯类化合物、其中间体、制备方法、药物组合物及应用 | |
WO2000075113A1 (fr) | Nouveaux derives carboxamide heterocycliques | |
WO2018196677A1 (zh) | 氟代烯丙胺衍生物及其用途 | |
NZ580237A (en) | Compounds with anti-cancer activity | |
JP2006160733A (ja) | シアノフルオロピロリジン誘導体を有効成分として含有する医薬 | |
JP6581745B2 (ja) | 抗b型肝炎ウイルスのピラゾール−オキサゾリジノン系化合物 | |
EP2599774B1 (en) | Condensed pyridine compounds as cb2 cannabinoid receptor ligands | |
WO2023143236A1 (zh) | 2h-吲唑-7-甲酰胺类化合物、制备方法、药物组合物和应用 | |
TW202200551A (zh) | 用於治療冠狀病毒感染之具有共價修飾的sars-cov-2抑制劑 | |
WO2010073235A1 (en) | Ppar agonist compositions and methods of use | |
WO2020192650A1 (zh) | 酰胺类化合物制备方法及其在医药领域的应用 | |
WO2020221006A1 (zh) | 一种bet蛋白抑制剂、其制备方法及用途 | |
WO2022121517A1 (zh) | 一种苄胺或苄醇衍生物及其用途 | |
JP2023516102A (ja) | ヒストン脱アセチル化酵素6阻害剤としての1,3,4-オキサジアゾール誘導体化合物、およびそれを含む医薬組成物 | |
CN109438513B (zh) | 含有取代膦酰胺酯的ido1抑制剂、其制备方法及应用 | |
WO2023116824A1 (zh) | 哒嗪酮类化合物及其制备方法、药物组合物和应用 | |
JP2921760B2 (ja) | フタルイミド誘導体及びそれら誘導体を含んでなる医薬 | |
WO2021093172A1 (zh) | Hbv抑制剂及其用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |